Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive advanced solid tumors (non-breast, non-gastric)
CTR20211816Phase 2Completed
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in HER2-overexpressing solid tumor, sponsored by Zhejiang Medicine Co., Ltd.. Started Aug 2021; status: completed.
02
Drugs
anvatabart opadotin
03
Conditions
HER2-overexpressing solid tumor
Beyond the preview
Go deeper on CTR20211816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211816.